Author

Muhammed İkbal Kılıç

Observed names: Kılıç, Muhammed İkbal, Muhammed İkbal KILIÇ

Institution: Aksaray University

Observed institution: Aksaray University

ORCID: 0000-0002-6762-0795

Observed ORCID: 0000-0002-6762-0795

OpenAlex ID: A5054286376

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

2023 · Murat Bektaş, Servet Yüce, et al. · Inflammopharmacology · 7

Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study

2024 · Ramazan Çakmak, Servet Yüce, et al. · Scientific Reports · 3

Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study

2024 · Murat Bektaş, Mustafa Ay, et al. · International Immunopharmacology · 3

Predictors of Mortality in Severe and Critical COVID-19 Patients Receiving High Dose Intravenous Anakinra

2023 · Murat BEKTAŞ, Muhammed İkbal KILIÇ · Journal of Immunology and Clinical Microbiology · 1

Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study

2023 · Murat Bektas, Ramazan Çakmak, et al.

Individualized High Dose Intravenous Anakinra Treatment is Safe and Effective in Patients with COVID-19 Associated Cytokine Storm Accompanying Cancer: A Retrospective Matched Study

2022 · Murat Bektaş, Murat Bektaş, et al.

Works count: 7

Citation count: 14

H-index: 3

I10-index: